Giannicola Genovese

1 month ago | cell.com | Zilong Zhao |Benxia Hu |Yalan Deng |Melinda Soeung |Jun Yao |Lanxin Bei | +25 more

Keywords sickle cell disease renal medullary carcinoma ferroptosis genomic architecture alteration Hi-C H2S SLC7A11 SMARCB1 immune checkpoint inhibitors CD8+ T cells Introduction Sickle cell disease (SCD), the most prevalent inherited blood disorder,1 arises from the homozygous HbS mutation (GAG>GTG: βGlu6Val), causing hemoglobin abnormalities that make red blood cells (RBCs) assume a sickle or crescent shape.2 Individuals with SCD have RBCs prone to hemolysis, leading to vaso-occlusive...

1 month ago | cell.com | Zilong Zhao |Benxia Hu |Yalan Deng |Melinda Soeung |Jun Yao |Lanxin Bei | +25 more

Keywords sickle cell disease renal medullary carcinoma ferroptosis genomic architecture alteration Hi-C H2S SLC7A11 SMARCB1 immune checkpoint inhibitors CD8+ T cells Introduction Sickle cell disease (SCD), the most prevalent inherited blood disorder,1 arises from the homozygous HbS mutation (GAG>GTG: βGlu6Val), causing hemoglobin abnormalities that make red blood cells (RBCs) assume a sickle or crescent shape.2 Individuals with SCD have RBCs prone to hemolysis, leading to vaso-occlusive...

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.